David Traylor is Senior Managing Director at Golden Eagle Partners, a firm he originally founded in to advise life science companies. After advising on various transactions in the life science sector, he took an interest in the cannabis sector and started advising cannabis companies before eventually re-founding Golden Eagle Partners in 2014 to focus on advising companies across the cannabis sector. Before Golden Eagle Partners, David served at leading investment banking firms including Pacific Growth Equities, Caris & Company, and Headwaters MB. During his banking tenures he has advised private and public biotechnology and medical device companies in various transactions including IPOs, public offerings, private offerings, mergers and acquisitions totaling over $500 million in value.



During our conversation we discuss: 



The current cannabis investment outlook Challenges cannabis innovators face when raising capital How federal prohibition affects innovation and investment into cannabis technologies Emerging international markets that may eventually outpace the US Preview of the Capital Markets Workshop taking place at CannMed 23 



Thanks to This Episode's Sponsor: Golden Eagle Partners



Golden Eagle Partners are transactional experts that have combined experience in the early stages of the cannabis and life science sectors, which help them to confidently close strategic and financing transactions that match the near- and long-term goals of their clients. They specialize in mergers, acquisitions, reverse mergers, financings, and incremental transactions such as licensing, joint ventures, and co-development arrangements. 



Learn more at goldeneaglepartners.com



Additional Resources



A Weed Grows in Davos [Rolling Stone]Golden Eagle PartnersSubmit an Abstract for CannMed 23Review the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]Healthcare Provider Medical Cannabis Research Study